Kang Jeong Suk, Wang Xu-Ping, Miner Jeffrey H, Morello Roy, Sado Yoshikazu, Abrahamson Dale R, Borza Dorin-Bogdan
Division of Nephrology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232-2372, USA.
J Am Soc Nephrol. 2006 Jul;17(7):1962-9. doi: 10.1681/ASN.2006020165. Epub 2006 Jun 12.
Mutations in COL4A3/4/5 genes that affect the normal assembly of the alpha3/4/5(IV) collagen network in the glomerular basement membrane (GBM) cause Alport syndrome. Patients progress to renal failure at variable rates that are determined by the underlying mutation and putative modifier genes. Col4a3(-/-) mice, a model for autosomal recessive Alport syndrome, progress to renal failure significantly slower on the C57BL/6 than on the 129X1/Sv background. Reported here is a novel strain-specific alternative collagen IV isoform switch that is associated with the differential renal survival in Col4a3(-/-) Alport mice. The downregulation or the absence of alpha3/4(IV) collagen chains in the GBM of Lmx1b(-/-) and Col4a3(-/-) mice was found to induce ectopic deposition of alpha5/6(IV) collagen. The GBM deposition of alpha5/6(IV) collagen was abundant in C57BL/6 Col4a3(-/-) mice but almost undetectable in 129X1/Sv Col4a3(-/-) mice. This strain difference was due to overall low expression of alpha6(IV) chain and alpha5/6(IV) protomers in the tissues of 129X1/SvJ mice, a natural Col4a6 knockdown. In (129 x B6)F1 Col4a3(-/-) mice, the amount of alpha5/6(IV) collagen in the GBM was inherited in a mother-to-son manner, suggesting that it is controlled by one or more X-linked loci, possibly Col4a6 itself. Importantly, high levels of ectopic alpha5/6(IV) collagen in the GBM were associated with approximately 46% longer renal survival. These findings suggest that alpha5/6(IV) collagen, the biologic role of which has been hitherto unknown, may partially substitute for alpha3/4/5(IV) collagen. Therapeutically induced GBM deposition of alpha5/6(IV) collagen may provide a novel strategy for delaying renal failure in patients with autosomal recessive Alport syndrome.
影响肾小球基底膜(GBM)中α3/4/5(IV)胶原网络正常组装的COL4A3/4/5基因突变会导致奥尔波特综合征。患者进展至肾衰竭的速度各不相同,这取决于潜在的突变和假定的修饰基因。Col4a3(-/-)小鼠是常染色体隐性奥尔波特综合征的模型,在C57BL/6背景下进展至肾衰竭的速度明显比在129X1/Sv背景下慢。本文报道了一种新的品系特异性替代性IV型胶原异构体转换,它与Col4a3(-/-)奥尔波特小鼠不同的肾脏存活率相关。研究发现,Lmx1b(-/-)和Col4a3(-/-)小鼠GBM中α3/4(IV)胶原链的下调或缺失会诱导α5/6(IV)胶原的异位沉积。α5/6(IV)胶原在C57BL/6 Col4a3(-/-)小鼠的GBM中大量沉积,但在129X1/Sv Col4a3(-/-)小鼠中几乎检测不到。这种品系差异是由于129X1/SvJ小鼠(一种天然的Col4a6基因敲低小鼠)组织中α6(IV)链和α5/6(IV)原聚体的整体低表达。在(129×B6)F1 Col4a3(-/-)小鼠中,GBM中α5/6(IV)胶原的量以母传子的方式遗传,这表明它受一个或多个X连锁基因座控制,可能是Col4a6本身。重要的是,GBM中高水平的异位α5/6(IV)胶原与肾脏存活率延长约46%相关。这些发现表明,其生物学作用迄今未知的α5/6(IV)胶原可能部分替代α3/4/5(IV)胶原。治疗性诱导GBM沉积α5/6(IV)胶原可能为延缓常染色体隐性奥尔波特综合征患者的肾衰竭提供一种新策略。